# Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Source: https://onco.cc/trials/nct06245356/  
OnCo record `nct06245356` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of trifluridine/tipiracil, fOLFOX (5-FU, leucovorin, oxaliplatin), panitumumab, bevacizumab (glioblastoma use) and other drugs in colorectal cancer, run by UNICANCER, now recruiting.

## Summary

Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer is a phase 2, interventional study registered as NCT06245356 by UNICANCER, with a registry enrolment figure of 73 participants, started 2025-03-21 and due to reach its primary completion in 2026-10-22. Interventions recorded: Lonsurf; Oxaliplatin; Panitumumab; Bevacizumab; Trastuzumab; Nivolumab. Conditions listed: Metastatic Colorectal Cancer; Metastatic Gastroesophageal Adenocarcinoma; DPD Deficiency. Primary outcome: Treatment specific safety. Colorectal eligibility wording from the registry: "Histological or cytological documentation of adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower oesophagus, gastroesophageal junction and gastric)". Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: TRIFLUOX-DP
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06245356
- Phase: 2
- Setting: TRIFLUOX-DP: Safety of Trifluridine/Tipiracil as Replacement of Fluoropyrimidines (5-fluorouracil and Capecitabine) Based Chemotherapy as First Line Metastatic Colorectal or Gastroesophageal Cancer Regimens in Patients With Dihydropyrimidine Dehydrogenase Deficiency: a Phase II Trial
- Sponsor: UNICANCER
- Enrolled: 73

## Sources

- ClinicalTrials.gov NCT06245356: https://clinicaltrials.gov/study/NCT06245356

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Panitumumab](https://onco.cc/drugs/panitumumab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/)
- companies: [Servier](https://onco.cc/companies/servier/), [UNICANCER](https://onco.cc/companies/unicancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06245356.json